Pharmaceutical Supply – Labetalol Hydrochloride Injection

The contract is for the supply of Labetalol Hydrochloride Injection, USP, in 5 mg/mL strength, packaged in 40 mL vials, with complete packaging, labeling, and delivery services that meet all federal and military regulatory standards. The product must adhere strictly to U.S. Pharmacopeia guidelines and be suitable for use within Department of Defense medical facilities, with performance centered at Fort Stewart, Georgia, under the zip code 31314-5185. The procurement falls under NAICS code 325412, indicating pharmaceutical preparation manufacturing, and is structured as a subcontract within the Medical Supply Chain Pharm FSA framework. Responses are due by August 10, 2026, with the solicitation posted on August 2, 2026, through the DIBBS platform, and the contracting entity is part of the Department of Defense. While the solicitation number and point of contact are not listed, vendors are expected to comply with all military-specific requirements for inventory management, traceability, shipment timing, and documentation. The contract does not specify a set-aside classification, meaning it is open to all eligible suppliers meeting the technical and regulatory criteria for pharmaceutical products used in defense medical operations.